5-fluorouracil (5-FU) is one of the most commonly used antineoplastic drugs in the anticancer therapy. The hand-foot (HF) syndrome (palmar-plantar erythrodysesthesia) is an adverse effect frequently related to long-term i.v. administration of 5-FU or its orally applicable prodrug capecitabine. Its severity can even lead to interruption of the otherwise effective anticancer therapy. Tentative practice in some clinics has shown that topical application of 10% uridine ointment is beneficial for calming down the HF syndrome. This study is focused on verifying the alleged protective activity of uridine in the in vitro model of cultured human keratinocyte cell line HaCaT. We also tested the protective effects of thymidine alone or uridine-thymidine combination. The cellular viability time progression was measured in order to evaluate the effect of protective agents by three different types of cytopathogenicity tests-NTCA test (non-destructive test of cellular activity), modified MTT test and RTCA (real-time cell analyser, Roche). All three methods proved the ability of uridine and uridine-thymidine combination to protect keratinocytes against 5-FU damage in vitro. While thymidine alone did not show any remarkable effect, the thymidine-uridine combination demonstrated enhanced protective activity compared to uridine alone. Our findings provided the supporting rationale for using uridine or uridine-thymidine ointments in the HF syndrome local therapy.

Hospital Pharmacy 1st Faculty of Medicine Charles University Prague and General Teaching Hospital 12108 Prague Czech Republic

Zobrazit více v PubMed

Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clinical Cancer Research. 1998;4(2):325–329. PubMed

Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology. 2008;26(7):1086–1092. PubMed PMC

Lokich JJ, Ahlgren D, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. Journal of Clinical Oncology. 1989;7(4):425–432. PubMed

Streit M, Jaehde U, Stremetzne S, et al. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regime. Annals of Oncology. 1997;8(11):163–165. PubMed

Biganzoli L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7(supplement 6):29–35. PubMed

von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European Journal of Cancer. 2008;44(6):781–790. PubMed

Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. European Journal of Oncology Nursing. 2007;11(3):238–246. PubMed

Barth J. Uridin-Hand-Fuß-Salbe und Uridin-Haftpaste. Krankenhauspharmazie. 2000;21(12):625–628.

Netikova I. 10% Uridine ointment—experiences. Onkologická Farmacie. 2011;1(1):14–16.

von Pestka A, Partyka D, Gratz H. Erste klinishe studie mit der 10% uridincreme in polen. Onkologische Pharmazie. 2008;10(2):10–11.

Netikova I, Sedlackova E, Konopasek B, Petruzelka L. Therapy of palmar-plantar erythrodysesthesia after continual fluoropyrimidin administration with 10% uridin ointment. Journal of Clinical Oncology. 2009;27(supplement 15)e20690

Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW. High-dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Research. 1982;42(10):3964–3970. PubMed

Leyva A, van Groeningen CJ, Kraal I, et al. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Research. 1984;44(12, part 1):5928–5933. PubMed

Bamat MK, Tremmel R, O.'Neil JD, von Borstel R. Uridine triacetate: an orally administered, life-saving antidote for 5-FU overdose. Journal of Clinical Oncology. 2010;28, supplement 15 abstract 9084.

Noordhuis P, Holwerda U, van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Annals of Oncology. 2004;15(7):1025–1032. PubMed

Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(5):1795–1799. PubMed PMC

O’Dwyer PJ, King SA, Hoth FD, Leyland-Jones B. Role of thymidine in biochemical modulation: a review. Cancer Research. 1987;47(15):3911–3919. PubMed

Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. Journal of Cell Biology. 1988;106(3):761–771. PubMed PMC

Netikova I, Bursikova E, Vesely P, Prchalova M, Kleibl Z, Matouskova E. A simple non-destructive test of cellular activity (NTCA) for in vitro assessment of cancer cell chemosensitivity/resistance. Anticancer Research. 2007;27(4):2331–2337. PubMed

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 1983;65(1-2):55–63. PubMed

Atienzar FA, Tilmant K, Gerets HH, et al. The use of real-time cell analyzer technology in drug discovery: defining optimal cell culture conditions and assay reproducibility with different adherent cellular models. Journal of Biomolecular Screening. 2011;16(6):575–587. PubMed

Bonifas J, Scheitza S, Clemens J, Blömeke B. Characterization of N-acetyltransferase 1 activity in human keratinocytes and modulation by para-phenylenediamine. Journal of Pharmacology and Experimental Therapeutics. 2010;334(1):318–326. PubMed

Tamura T, Kuwahara A, Kadoyama K, et al. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. International Journal of Medical Sciences. 2011;8(5):406–412. PubMed PMC

Takimoto CH, Yee LK, Venzon DJ, et al. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clinical Cancer Research. 1999;5(6):1347–1352. PubMed

Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. British Journal of Clinical Pharmacology. 2003;55(3):252–263. PubMed PMC

Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G. Lack of contribution of dihydrofluorouracil and α-fluoro-β- alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes. Anti-Cancer Drugs. 2004;15(10):969–974. PubMed

Benson HA. Transdermal drug delivery: penetration enhancement techniques. Current Drug Delivery. 2005;2(1):23–33. PubMed